Close Many team members at Unicorn Nest are Ukrainians affected by Russian aggression. We do our best to solve any issues and answer your questions in the shortest possible time frames but some delays are possible.

CTTM

Overview

Unlock datapoints

Portfolio analytics

Team

Investments

News & Media

Add fund to favorites
info
Save this fund for later to form your own custom list of funds
This summary is composed by our algorithm based on the analysis of the deals. If you think that some of this information is not accurate, please let us know about it and provide any supporting evidences if possible. Such cases will be analyzed by our ML-algorithm and implemented in our database, which will improve this summary.
Total investments 2
Average round size
info
The average size of a deal this fund participated in
$1M
Portfolio companies 1
Lead investments 0
Follow on index
info
How often the fund supports its portfolio startups at next rounds
0.50
Key employees Soon

Areas of investment

  • Medical Device
  • Diabetes
Summary

Among the most popular portfolio startups of the fund, we may highlight Defymed. Besides, a startup requires to be at the age of 4-5 years to receive the investment from the fund. Among the most successful fund investment fields, there are Medical Device, Diabetes.

The top activity for fund was in 2011. The fund is constantly included in less than 2 deals per year. Deals in the range of 1 - 5 millions dollars are the general things for fund.

The usual cause for the fund is to invest in rounds with 3-4 partakers. Despite the CTTM, startups are often financed by CeeD (Centre Europu00e9en d'u00e9tude du diabu00e8te), Statice, Emertec Gestion. The meaningful sponsors for the fund in investment in the same round are CeeD (Centre Europu00e9en d'u00e9tude du diabu00e8te), Statice, Emertec Gestion. In the next rounds fund is usually obtained by Emertec Gestion, CeeD (Centre Europu00e9en d'u00e9tude du diabu00e8te), Cap Innov'Est.

Read more

Look at other 50 related and similar funds Collapse list
Fund NameLocation
Blue Water Life Science Fund California, Mill Valley, United States
BS Group -
Chongqing Sanxia Paints China, Chongqing, Jiangjin
Core Capital Manila, Philippines
Crescent Cove Advisors California, San Francisco, United States
Do Ventures Jamaica, Saint James, Vietnam
G5 Capital LLC -
Gongqingcheng Xingchuang Wenhua Touzi Guanli Youxian Gongsi China, Jiangxi, Jiujiang
Group One -
Hongtai Hurong Changning, China, Shanghai
Lever VC New York, New York, United States
MINTS Ann Arbor, Michigan, United States
Nia Impact Capital -
Pilot Invest -
Qingyan Venture Capital Management China, Hunan, Liuyang
Startupbootcamp HighTechXL Eindhoven, Netherlands, North Brabant
TAIHO Industrial Japan, Kagawa Prefecture, Takamatsu
Take-Two Interactive New York, New York, United States
Thunder Road Capital Canada, Ontario, Toronto

Notable deals

CompanyIndustryRound SizeDateInvestorsLocation

Defymed

Diabetes
Medical Device
$2M27 Oct 2015 Strasbourg, Grand Est, France

Defymed

Diabetes
Medical Device
04 Apr 2011 Strasbourg, Grand Est

Review

  • No reviews are submitted yet.
Do you want more?
We provide dozens of additional datapoints about this fund.
Sign up and get access to full fund profile and advanced analysis.
Full team
Industries heatmap
Stages heatmap
Georgaphy breakdown
Coinvestors
Portfolio analysis
Performance indexes
Latest highlights
Unlock all data
Do you represent CTTM?
Get access to manage this page
Get in touch
Found incorrect info? Let us know!

Wait!
You can raise money with us faster

Get matched with relevant funds

Find decision makers data

Connect with investors by email

Remind me later
...and save more than 200 hours*
*-Our recommendation and outreach system saves up to 200 hours of founder time on fundraising for seed and series A+ startups
We use LinkedIn only to verify your account. We don't import or message your contacts, nor post on your behalf.
By creating an account, you agree to our Terms of Service and Privacy Policy.
Crunchbase icon

Content report

The following text will be sent to our editors: